The bill would bar writing off advertising expenses for unhealthy food marketed to children.
Legislation in the House would prohibit the distributions of federal subsidies until a system is in place to counter fraud.
The FDA said menthol cigarettes "raise critical public health questions" as it weighs possible new regulations.
Congressional Republicans and business groups on Tuesday demanded more information from the administration about the decision.
Medical trade groups are resisting a potential change to regulations on medical imaging and radiation therapy equipment that they worry would lead to lax standards.
In recent weeks, organizations have sent letters to the Centers for Medicare and Medicaid Services (CMS) urging the agency not to lower standards for the maintenance of devices that perform MRIs and other procedures.
Howard Shelanski, who only reported for duty a week ago, has turned down an invitation to testify about the decision.
Federal drug regulators have approved for marketing the first medical device that uses brain waves to help diagnose attention deficit hyperactivity disorder (ADHD) in children younger than 18 years old.
The device records the frequency of different kinds of electrical impulses from neurons in the brain, then compares them to help determine whether a child has ADHD. Children with the condition tend to have a higher ratio of two different brain wave frequencies.
The chairmen of a pair of House subcommittees want to question the Obama administration's regulations chief over the decision to delay a key component of the Affordable Care Act.
For Howard Shelanski, the June 23 grilling would be a baptism under fire, since he reported for duty less than a week ago.
Sen. Mike Enzi questioned the administration’s authority to postpone enactment of the contentious employer mandate.
The Obama administration is planning to give generic drug companies new powers to update their labels without needing to wait for their brand name counterparts.
The announcement comes the week after the Supreme Court ruled that generic drugmakers could not be sued because their product is too dangerous for the market.
In its spring roadmap for new regulations, the Food and Drug Administration declared that it intends to propose a rule in September that will make it easier for drug companies to update their labeling.